Articles written by Vandana Singh - Benzinga

BrightSpring Extends Rally With Solid Q1, Upgraded Fiscal 2026 Forecast

BrightSpring Extends Rally With Solid Q1, Upgraded Fiscal 2026 Forecast

BrightSpring shares rise after Q1 earnings beat, revenue growth and raised FY26 guidance; analysts cite momentum but note valuation premium.

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept shares rise after Phase 2 ALS data shows 87% lower death risk; earnings miss, revenue shortfall, and raised 2026 sales outlook.

Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar

Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar

Contineum stock rises after PIPE-791 pain trial shows safety and early efficacy signals, with mixed technicals and strong cash runway.

Moderna's Legal Hit Steals Spotlight From Strong Sales

Moderna's Legal Hit Steals Spotlight From Strong Sales

MRNA revenue hits $389M, beating Wall Street estimates. Despite a Q1 loss, Moderna eyes 10% growth and new flu vaccine approvals in 2026.

Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules

Eli Lilly Jumps As Earnings Beat Meets FDA Tightening Drug Compounding Rules

Eli Lilly lifts 2026 outlook after Q1 beat; FDA targets compounded GLP-1 drugs, tightening rules on semaglutide, tirzepatide, liraglutide.

Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression

Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression

FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding its use beyond depression in a large market.

AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters

AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters

FDA panel backs AstraZeneca prostate drug combo but rejects breast cancer therapy, signaling mixed outlook for oncology pipeline.

Baxter Profit Plunges 35% As Tariffs, Costs Bite

Baxter Profit Plunges 35% As Tariffs, Costs Bite

Baxter tops earnings, but profit plunges 35% as tariffs and manufacturing costs rise; outlook for 2026 remains intact.

Cigna Raises Outlook, Flags Individual Exchange Exit And Strategic Review Of eviCore

Cigna Raises Outlook, Flags Individual Exchange Exit And Strategic Review Of eviCore

Cigna beats Q1 estimates on Evernorth growth, raises outlook, but reports a dip in customer relationships and plans exchange exit.

Tenet Healthcare Blames Admissions Mix For Soft Q1 Sales

Tenet Healthcare Blames Admissions Mix For Soft Q1 Sales

Tenet Healthcare posts Q1 earnings beat but revenue miss as payer mix shifts and external disruptions weigh on performance.

Why Is Bristol-Myers Squibb Stock Trading Higher On Thursday?

Why Is Bristol-Myers Squibb Stock Trading Higher On Thursday?

Bristol-Myers Squibb beats Q1 2026 estimates as growth drugs lift revenue, while the legacy portfolio faces continued generic pressure.

Merck Swings To Quarterly Loss On Cidara Deal

Merck Swings To Quarterly Loss On Cidara Deal

Merck Q1 2026 results show oncology-led growth, vaccine weakness, and raised guidance after beating sales and loss estimates.

Labcorp Advances As AI Investments, Core Businesses Drive Growth

Labcorp Advances As AI Investments, Core Businesses Drive Growth

Labcorp shares rise after Q1 earnings beat and higher guidance, supported by diagnostics growth and investments in AI and robotics.

Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand

Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand

Eli Lilly beats Q1 estimates, lifts 2026 outlook as Mounjaro and Zepbound demand offsets pricing pressure and drives strong revenue growth.

Why Is Cardinal Health Stock Sinking Thursday?

Why Is Cardinal Health Stock Sinking Thursday?

Cardinal Health (CAH) stock falls despite an EPS beat in Q3 2026. Revenue missed estimates at $60.9B. Get the full earnings breakdown here.

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.

EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study

EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study

Telomir wins FDA IND clearance for Telomir-Zn in TNBC, enabling a Phase 1/2 study targeting epigenetic cancer pathways.

AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength

AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength

AbbVie Q1 2026 sales beat estimates as Skyrizi and Rinvoq drive growth, while Humira declines; company raises full-year EPS outlook.

PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers

PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers

PTC Therapeutics stock drops after PIVOT-HD update, as FDA approval doubts offset dose-based benefits and stable safety signals.

Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study

Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study

Pfizer reports Phase 3 data showing ELREXFIO improved progression-free survival versus standard therapy in multiple myeloma study.